

Prediagnostic Plasma Pyridoxal 5'-Phosphate (Vitamin B6) Levels and Invasive Breast Carcinoma Risk: The Multiethnic Cohort

Galina Lurie¹, Lynne R. Wilkens¹, Yurii B. Shvetsov¹, Nicholas J. Ollberding², Adrian A. Franke¹, Brian E. Henderson³, Laurence N. Kolonel¹, and Marc T. Goodman¹

Abstract

Background: Evidence from experimental and epidemiologic studies suggests that vitamin B6 may reduce the risk of breast cancer.

Methods: We examined the association of prediagnostic plasma concentrations of pyridoxal-5'-phosphate (PLP), an active form of vitamin B6, with postmenopausal breast cancer risk in a case-control study nested in the multiethnic cohort in Hawaii and Southern California, including 706 cases and 706 controls matched on date of birth, ethnicity, study site, date of blood draw, time of blood draw, hours of fasting before blood draw, and use of menopausal hormones. OR and 95% confidence intervals (CI) were calculated using conditional logistic regression models.

Results: Women with plasma PLP concentrations in the highest quartile had a 30% reduced risk of invasive breast cancer (CI: 0.50–0.98) as compared with the women in the lowest PLP quartile (P for trend = 0.02). The association seemed to be limited in cases with hormone receptor-positive tumors (P for heterogeneity = 0.04); and remained unchanged in the analysis restricted to women with blood samples collected more than one year before cancer diagnosis (OR = 0.69; CI: 0.48–0.99; P for trend = 0.03).

Conclusions: These data suggest that higher circulating levels of vitamin B6 are associated with a reduced risk of invasive postmenopausal breast cancer.

Impact: These results, in combination with information from two other prospective studies, suggest a role for vitamin B6 in the prevention of postmenopausal breast cancer. Additional studies are needed to further investigate potential heterogeneity of the vitamin B6 association with breast cancer risk by tumor hormone receptor status. *Cancer Epidemiol Biomarkers Prev*; 21(11); 1942–8. ©2012 AACR.

Introduction

Identification of molecular mechanisms underlying breast carcinogenesis is fundamental to the prevention of breast cancer, the most common malignancy among women (1). Although, many of the accepted breast cancer risk factors, such as age at menarche, parity, age at first full-term pregnancy, and age at menopause are difficult to modify, diet is a potentially modifiable factor. However, besides alcohol intake, no association of diet with postmenopausal breast cancer risk has been established (2).

Pyridoxal 5'-phosphate (PLP), the active form of vitamin B6 (3), serves as a cofactor in more than 100 enzymatic reactions (4). Vitamin B6 is involved in one-carbon

metabolism, a sequence of biochemical processes that enrich the cellular supply of methyl groups for DNA synthesis, repair, and methylation (5). Apart from its role as a coenzyme, vitamin B6 might affect carcinogenesis directly through inhibition of cell proliferation, oxidative stress, angiogenesis, and enhanced immune function (reviewed in ref. 6).

Results from studies of the association of dietary vitamin B6 intake (7–17) or circulating PLP levels (18–20) with breast cancer risk are inconsistent. A randomized trial of combined folic acid, vitamin B6, and vitamin B12 reported significantly reduced breast cancer risk among women in the treatment arm of older (≥ 65 years old) but not younger women (21). We investigated prediagnostic plasma levels of PLP in relation to invasive breast cancer risk among postmenopausal women in the multiethnic cohort (MEC) study.

Materials and Methods

Study design and population

This case-control study was nested within the biospecimen subcohort of the MEC, a large prospective

Authors' Affiliations: ¹University of Hawaii Cancer Center, Honolulu, Hawaii; ²Department of Health Studies, University of Chicago, Chicago, Illinois; and ³Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California

Corresponding Author: Galina Lurie, Cancer Research Center of Hawaii, 1236 Lauhala Street, Room 502E, Honolulu, HI 96813. Phone: 808-564-5981; Fax: 808-586-2982; E-mail: glurie@cc.hawaii.edu

doi: 10.1158/1055-9965.EPI-12-0717-T

©2012 American Association for Cancer Research.

study of residents of Hawaii and Southern California, which included 118,441 women (22). The population-based sampling frames for the MEC included rolls from drivers' licenses, voters' registration, and the Health Care Financing Administration and was targeted to 5 ethnic groups: African-American, Hawaiian, Japanese, Latino, and whites. At cohort entry, participants completed a self-administered, 26-page baseline questionnaire that included queries on demographic characteristics, anthropometry, medical history, family history of cancer, reproductive and menstrual history, cancer risk factors, and detailed questions on diet. The MEC biospecimen sub-cohort was established from 1996 through 2006, with the majority of recruitment occurring after 2001. All surviving cohort members still residing in the catchment area were recontacted and asked to provide biologic specimens, including blood samples. Blood samples were drawn at a clinical laboratory or at the participants' homes and were kept refrigerated and protected from light until processed on average within 3 hours of collection. After centrifugation, blood components were aliquoted into 0.5-mL cryovials and stored in the vapor phase of liquid nitrogen (-150°C). A total of 36,458 female cohort members contributed to the biorepository from which the cases and controls were selected for the present study. Although, the participants in the biospecimen sub-cohort were slightly more educated (mean 13.6 years vs. 12.7 years), were more likely to be nonsmokers (13% vs. 17%), and had a family history of cancer (46% vs. 42%) than nonparticipants, they were similar in relation to other exposures and were generally representative of all cohort members.

The study protocol was approved by the Institutional Review Boards of the University of Hawaii and the University of Southern California, and all participants signed informed consent.

Case ascertainment and control selection

Linkages of the cohort to the Surveillance, Epidemiology, and End Results cancer registries in Hawaii and California are conducted annually to identify incident breast cancer cases diagnosed during the follow-up period. Linkages to state death files and the National Death Index are conducted to identify deaths. Postmenopausal women participating in the biospecimen repository, who were diagnosed with primary invasive breast carcinoma before the most recent tumor registry linkage (December 31, 2010) and provided blood sample before breast cancer diagnosis were included in this analysis. Breast cancer cases were identified using the International Classification of Diseases for Oncology, 3rd edition, (codes C50.0–C50.9). Controls were randomly selected from the pool of postmenopausal women who were alive and free of a breast cancer diagnosis and individually matched to cases in a 1:1 ratio on study site, ethnicity, date of birth (± 1 year), date of blood draw (± 6 months), time of blood draw (morning hours), hours fasting before blood draw (<6 , 6 to <8 , 8 to <10 , ≥ 10), and use of menopausal

hormones at blood draw (none; current use of estrogen, progesterone, or combination of both). A total of 706 postmenopausal breast cancer cases and 706 matched controls were available for analysis. Tumor estrogen receptor (ER) and progesterone receptor (PR) status was available for 617 (87%) and 597 (85%) of the cases, respectively.

Laboratory analyses

Plasma samples were analyzed in the Analytical Biochemistry laboratory of the University of Hawaii Cancer Center (A.A. Franke, director) by laboratory personnel blinded to the case-control status of the samples. The PLP assay was based on the method of Rybak and Pfeiffer (23). Briefly, 150 μL freshly thawed plasma was mixed for 5 minutes with 10 μL aqueous $^2\text{H}_2$ -pyridoxal-5'-phosphate (internal standard, donated by Stephen P. Coburn, Purdue University, Fort Wayne, IN) and 50 μL 10% aqueous metaphosphoric acid (Sigma). After shaking with 200 μL CH_2Cl_2 , the supernatant aqueous layer was transferred into 350 μL round-bottom plates (MicroLiter Analytical Supplies) and 20 μL of the aqueous layer were injected into the liquid chromatography/tandem mass spectrometry (LC/MS-MS) system (model Accela and TSQ-Ultra from Thermo Scientific Inc.). PLP was separated on an Ascentis Express C18 column (150 mm \times 3.0 mm; 2.7 μm ; Supelco Inc.) and a 0.2 μm prefilter cartridge (2.1 mm i.d., ThermoFisher) at a flow rate of 0.6 mL/min with the following linear mobile phase gradient consisting of 5% aqueous acetic acid (A) and 0.1% formic acid in acetonitrile (B): %B = 4% for 1 minute then to 95% in 2 minutes, held at 95% for 1 minute and changed to 4% in 0.1 minute followed by equilibration for 4 minutes. Quantitation was conducted by tandem mass spectrometry after positive electrospray ionization in selected reaction monitoring mode by scanning the transitions m/z 248.0 to 150.1 (at 18 eV) and m/z 229.9 (at 14 eV) for PLP and m/z 250.0 to 152.0 (at 18 eV) for deuterated PLP (internal standard). Instrument settings were as follows: spray voltage, 4,000 V; sheath gas, nitrogen; sheath gas pressure, 45 arbitrary units; ion transfer capillary temperature, 350 $^{\circ}\text{C}$. External calibration was conducted with aqueous solutions of authentic standards (Sigma) in the range 5 to 1,000 nmol/L, and stock concentrations were determined by absorbance readings ($\epsilon = 5,070$ at 388 nm in water). On the basis of a total of 47 duplicate and 23 triplet samples, the intrabatch and interbatch coefficients of variation for PLP were 4.4% and 3.8%, respectively.

Statistical analysis

Statistical analysis was conducted using SAS 9.2. Conditional logistic regression models were used to calculate OR and 95% confidence intervals (CI) for the association of prediagnostic plasma PLP levels with postmenopausal breast cancer risk. Quartiles of the log-transformed PLP levels were based on the distribution among controls and entered into the models as

indicator variables with the lowest quartile as a reference category. Trend was assessed on the basis of a variable assigned to the median of the appropriate quartile for the transformed variable. To identify potential confounders, covariates were tested individually and jointly and were included in the models if they produced a >10% change in regression coefficients for PLP or were associated with breast cancer risk or PLP levels among controls. All final models were uniformly adjusted for the following baseline variables: [body mass index (BMI) kg/m²; continuous, log-transformed], education (continuous), family history of breast cancer among first-degree female relatives, age at menarche (≤ 12 , 13–14, and ≥ 15 years), parity (0, 1, 2–3, and ≥ 4) and age at first live birth (nulliparous, ≤ 20 , 21–25, and ≥ 26 years), years of contraceptive hormone use (none; < 5 , and ≥ 5 years), age at natural menopause (≤ 50 , 50–55, and > 55 years), oophorectomy, hysterectomy, smoking status (never, past, and current), average ethanol consumption (g/d; continuous, log-transformed), and hours of daily moderate and vigorous physical activity (continuous, log-transformed). We also examined the inclusion of one-carbon compounds, such as folic acid, 5-methyltetrahydrofolate, methylmalonic acid (indicator for vitamin B12), cysteine, homocysteine, methionine, choline, and betaine, but none of them individually or jointly influenced the association of PLP with breast cancer risk. A sensitivity analysis to examine whether the association of PLP with breast cancer risk was influenced by the time between blood collection and diagnosis was conducted. A Wald test was used to assess heterogeneity across subtypes of cancer by hormone receptor status and time from blood collection to diagnosis (≤ 1 year and > 1 year), using polytomous conditional logistic regression modeled via proportional hazards regression (24). Interactions between PLP and all covariates included in the models as well as other one-carbon compounds on the risk of postmenopausal breast cancer were examined using the Wald test of cross-product terms of PLP (as a trend variable) and each of the risk factors, in turn. All *P* values were 2-sided. *P* values < 0.05 were considered statistically significant.

Results

The mean age of the study participants at blood draw was 67.9 years (*SE*: 0.3; range: 58–87 years; Table 1). All matching variables were similar between cases and controls. Cases and controls were also similar with respect to years of education, ages at menarche, first live birth, menopause, and hours of daily moderate or vigorous physical activity. Cases were more likely than were controls to have had a family history of breast cancer and to be overweight or obese. Cases also had lower parity than controls, reported higher daily alcohol consumption, and were more likely to be current tobacco smokers. Cases had lower mean prediagnostic PLP levels than did controls

(83.3 nmol/L vs. 92.7 nmol/L). The percentage of cases with positive hormone receptor status tumors was higher among Japanese (86%), white (86%), and Hawaiian (85%) women than among Latino (78%) or black women (75%).

Among controls, mean PLP levels were significantly lower among obese (BMI ≥ 30 kg/m²; 78.4 ± 7.1 nmol/L), and overweight (BMI 25–29.9 kg/m²; 92.6 ± 5.2 nmol/L) women as compared with lean women (BMI < 25 kg/m²; 102.9 ± 4.5 nmol/L; *P* < 0.0004). Lower PLP levels were also observed among current smokers (75.2 ± 10.1 nmol/L) as compared with nonsmokers (97.7 ± 3.4 nmol/L; *P* = 0.01). Although, no statistically significant relation between ethnicity and PLP levels was observed (*P* = 0.30), PLP levels among Latina controls were significantly (*P* = 0.02) lower than among Japanese controls (76.8 ± 7.4 nmol/L vs. 102.8 ± 5.3 nmol/L). No statistically significant associations of PLP levels with other covariates were observed (data not shown).

Plasma PLP levels were inversely associated with postmenopausal breast cancer risk (Table 2). Women with PLP levels in the highest quartile had a 30% reduced risk of invasive breast cancer (95% CI: 0.50–0.98) as compared with the women with PLP levels in the lowest quartile (*P* trend = 0.02). This association remained unchanged after excluding cases (and their matched controls) whose blood was collected within 1 year of their breast cancer diagnosis. In the analysis stratified by tumor hormone receptor status, strong inverse associations of plasma PLP levels with breast cancer risk among women with ER-positive, PR-positive, and ER-positive/PR-positive tumors were observed. No significant associations of PLP with postmenopausal breast cancer risk were observed among women diagnosed with hormone receptor negative tumors (*P* for heterogeneity = 0.04 for the difference in breast cancer risk by hormone receptor status). No significant modification of the association of PLP levels with breast cancer risk was found by any of the covariates, including family history of breast cancer education, BMI, age at menarche, parity, age at first parturition, use of contraceptive and menopausal hormones, age at menopause, alcohol consumption, tobacco smoking and physical activity, age at blood collection, hours of fasting before blood collection, as well as other 1 one-carbon compounds (*P* > 0.16 ; data not shown), although there was some statistically significant (*P* = 0.04) heterogeneity by ethnicity. Among Latino women, no association of PLP with breast cancer risk was observed (Table 2).

Discussion

In this large prospective study of postmenopausal women, prediagnostic plasma PLP levels were inversely associated with invasive breast cancer risk. This association was strongest in women with hormone receptor positive tumors and remained unchanged in the analysis restricted to women whose blood was collected more than 1 year before cancer diagnosis. Inverse trends in the risk of postmenopausal breast cancer associated with

Table 1. Characteristics of participants of the breast cancer case-control study nested in the MEC in Hawaii and Southern California

| Participant characteristics | Cases <i>n</i> = 706 | Controls <i>n</i> = 706 | <i>P</i> ^a |
|---|-------------------------|----------------------------|-----------------------|
| Mean age (<i>SD</i>) at blood draw (yrs) | 67.9 (7.5) | 67.9 (7.5) | Matching variable |
| Hours of fasting (<i>SD</i>) before blood draw | 12.7 (2.9) | 12.6 (2.9) | Matching variable |
| Ethnicity, <i>N</i> (%) | | | Matching variable |
| African-American | 106 (15) | 106 (15) | |
| Hawaiian | 66 (9) | 66 (9) | |
| Japanese | 254 (36) | 254 (36) | |
| Latino | 132 (19) | 132 (19) | |
| White | 148 (21) | 148 (21) | |
| Study site | | | Matching variable |
| Hawaii | 419 (59) | 419 (59) | |
| California | 287 (41) | 287 (41) | |
| Years of education, mean (<i>SD</i>) | 13.6 (3.1) | 13.6 (3.1) | 0.89 |
| History of breast cancer among first-degree relatives, <i>N</i> (%) | 109 (15) | 82 (12) | 0.04 |
| BMI, mean (<i>SD</i>) | 26.1 (5.4) | 26.7 (5.2) | 0.01 |
| <25 | 290 (41) | 357 (51) | |
| 25–29.9 | 260 (37) | 206 (29) | |
| ≥30 | 156 (22) | 143 (20) | 0.001 |
| Age at menarche (yrs), mean (<i>SD</i>) | 13.0 (1.6) | 13.1 (1.6) | 0.42 |
| Age at natural menopause, mean (<i>SD</i>) | 49.6 (4.8) | 49.2 (4.6) | 0.28 |
| Parity | | | |
| Nulliparous | 94 (13) | 73 (10) | |
| 1 | 80 (11) | 78 (11) | |
| 2–3 | 334 (47) | 317 (45) | |
| ≥4 | 198 (28) | 238 (34) | 0.08 |
| Age at first live birth, mean (<i>SD</i>) | 23.7 (4.6) | 23.5 (4.5) | 0.50 |
| Current use of menopausal hormones | 190 (27) | 190 (27) | Matching variable |
| Alcohol consumption (ethanol, g/d), mean (<i>SD</i>) | 4.8 (15.5) | 3.6 (11.0) | 0.09 |
| Current smoking status <i>n</i> (%) | | | |
| Nonsmoker | 607 (87) | 626 (90) | |
| Smoker | 92 (13) | 72 (10) | 0.10 |
| Moderate or vigorous physical activity (h/d), mean (<i>SD</i>) | 1.2 (1.3) | 1.2 (1.3) | 0.66 |
| PLP (nmol/L), mean (<i>SD</i>) | 83.3 (78.0) | 92.7 (85.3) | 0.02 |

NOTE: Cases and controls were matched on age of birth (± 1 year), study site (Hawaii or California), ethnicity, date of blood draw (± 6 months), hours fasting before blood draw (<6, 6 to <8, 8 to <10, ≥ 10), and use of menopausal hormones at blood draw (none; estrogen alone; progestin alone, combined estrogen and progestin).

^a*P* values from χ^2 test (for categorical variables) and from *t* test (for continuous variables).

higher PLP levels were generally consistent in all ethnic groups, with the exception of Latinas among whom PLP was (nonsignificantly) positively related to risk. We also found comparatively low PLP levels among Latina controls and a higher percentage of hormone-receptor negative tumors among Latina cases than among cases from other ethnicities. However, we were limited by our sample size to further explore these population subgroups.

Results from 3 other prospective studies of the association of circulating PLP levels with postmenopausal breast cancer risk have been reported (18–20). In accordance with our findings, an inverse relation of PLP to postmenopausal breast cancer risk was observed in the

Women's Health Study among 521 postmenopausal cases and 520 controls (RR = 0.64; 95% CI: 0.42–0.99, comparing the highest and lowest quintiles; ref. 20). Although not statistically significant, an inverse association of plasma PLP to risk among 487 postmenopausal breast cancer cases and matched controls in the Nurses' Health Study was suggested (RR = 0.66; CI: 0.43–1.01, comparing the highest and lowest quintiles; ref. 19). No association of serum PLP with risk was found in a smaller study of 109 postmenopausal breast cancer cases and matched controls nested within the Washington County Cohort (18). Although, vitamin B6 intake was inversely associated with breast cancer in 2 studies (8, 17), most studies have

Table 2. Association of pyridoxal 5'-phosphate prediagnostic plasma levels with invasive breast cancer risk

| | Quartile 1 (≤41.1 nmol/L) | Quartile 2 (41.2–66.0 nmol/L) | Quartile 3 (66.1–116.6 nmol/L) | Quartile 4 (>116.6 nmol/L) | <i>P</i> _{trend} | <i>P</i> ^b |
|---|------------------------------|----------------------------------|-----------------------------------|-------------------------------|---------------------------|-----------------------|
| All participants (706 cases/706 controls) | | | | | | |
| <i>N</i> cases per controls | 198/177 | 197/176 | 165/176 | 146/177 | | |
| OR (95% CI) ^a | 1.00 (reference) | 0.91 (0.66–1.25) | 0.77 (0.55–1.08) | 0.70 (0.50–0.98) | 0.02 | |
| Excluding cases (and matched controls) with blood collection within 1 yr of diagnosis | | | | | | |
| <i>N</i> cases per controls | 165/146 | 165/149 | 137/146 | 122/148 | | |
| OR (95% CI) ^a | 1.00 (reference) | 0.88 (0.63–1.24) | 0.74 (0.51–1.07) | 0.69 (0.48–0.99) | 0.03 | 0.99 |
| Stratified according to the tumor ER/PR status | | | | | | |
| ER+ | | | | | | |
| <i>N</i> cases per controls | 154/125 | 140/125 | 115/129 | 92/122 | | |
| OR (95% CI) ^a | 1.00 (reference) | 0.80 (0.54–1.18) | 0.58 (0.38–0.90) | 0.55 (0.36–0.84) | 0.002 | |
| ER– | | | | | | |
| <i>N</i> cases/controls | 28/34 | 32/30 | 30/23 | 26/29 | | |
| OR (95% CI) ^a | 1.00 (reference) | 1.31 (0.47–3.69) | 2.35 (0.79–6.98) | 0.94 (0.34–2.62) | 0.86 | 0.09 |
| PR+ | | | | | | |
| <i>N</i> cases per controls | 128/95 | 119/105 | 90/113 | 77/101 | | |
| OR (95% CI) ^a | 1.00 (reference) | 0.73 (0.48–1.11) | 0.52 (0.32–0.83) | 0.56 (0.35–0.89) | 0.006 | |
| PR– | | | | | | |
| <i>N</i> cases per controls | 45/56 | 51/46 | 48/35 | 39/46 | | |
| OR (95% CI) ^a | 1.00 (reference) | 1.24 (0.61–2.52) | 1.70 (0.80–3.61) | 0.88 (0.41–1.89) | 0.88 | 0.06 |
| ER+/PR+ | | | | | | |
| <i>N</i> cases per controls | 125/92 | 117/105 | 88/110 | 76/99 | | |
| OR (95% CI) ^a | 1.00 (reference) | 0.71 (0.47–1.09) | 0.53 (0.33–0.85) | 0.58 (0.37–0.92) | 0.01 | |
| ER–/PR– | | | | | | |
| <i>N</i> cases per controls | 24/31 | 30/29 | 28/20 | 25/27 | | |
| OR (95% CI) ^a | 1.00 (reference) | 1.63 (0.50–5.36) | 3.46 (1.02–11.77) | 1.09 (0.35–3.35) | 0.70 | 0.04 |
| Stratified according to race/ethnicity | | | | | | |
| Black (106 cases/106 controls) | | | | | | |
| <i>N</i> cases per controls | 40/30 | 39/21 | 15/21 | 12/30 | | |
| OR (95% CI) ^a | 1.00 (reference) | 1.17 (0.46–3.00) | 0.27 (0.07–1.03) | 0.12 (0.03–0.46) | 0.002 | |
| Hawaiian (66 cases/66 controls) | | | | | | |
| <i>N</i> cases per controls | 23/15 | 15/22 | 15/10 | 13/19 | | |
| OR (95% CI) ^a | 1.00 (reference) | 0.15 (0.03–0.86) | 0.31 (0.04–2.38) | 0.15 (0.03–0.78) | 0.06 | |
| Japanese (254 cases/254 controls) | | | | | | |
| <i>N</i> cases per controls | 62/55 | 58/55 | 65/72 | 69/72 | | |
| OR (95% CI) ^a | 1.00 (reference) | 0.82 (0.44–1.52) | 0.69 (0.38–1.26) | 0.72 (0.40–1.30) | 0.25 | |
| Latino (132 cases/132 controls) | | | | | | |
| <i>N</i> cases per controls | 38/41 | 39/37 | 31/32 | 24/22 | | |
| OR (95% CI) ^a | 1.00 (reference) | 1.32 (0.54–3.27) | 1.03 (0.42–2.54) | 2.02 (0.79–5.18) | 0.25 | |
| White (148 cases/148 controls) | | | | | | |
| <i>N</i> cases per controls | 35/32 | 46/41 | 39/41 | 28/34 | | |
| OR (95% CI) ^a | 1.00 (reference) | 0.54 (0.23–1.27) | 0.65 (0.27–1.60) | 0.57 (0.24–1.33) | 0.32 | 0.04 |

^aOR and 95% CI from conditional logistic regression models including cases and controls matched on date of birth (± 1 year), study site, ethnicity, date of blood draw (± 6 months), hours fasting before blood draw (<6, 6 to <8, 8 to <10, ≥ 10), and hormone replacement therapy use at blood draw (none; estrogen alone, progestin alone, estrogen, and progestin) and adjusted for education, family history of breast cancer, BMI (continuous, kg/m²), age at menarche, parity, age at first parity, use of contraceptive hormones (none, <5 years ≥ 5 years), oophorectomy, hysterectomy, age at natural menopause, current smoking status, ethanol consumption (continuous, g/d), hours of daily moderate/vigorous physical activity.

^b*P* for heterogeneity of PLP association with breast cancer risk by ethnicity, time between blood collection and diagnosis, and tumor hormone receptor status.

not found its association with breast cancer risk (7, 9–16). A significant reduction of breast cancer risk was found among older women (age ≥ 65 years), but not younger women, in the randomized trial of folic acid, vitamin B6, and vitamin B12 (21). Although, it is not possible to distinguish the affects attributable to vitamin B6, folic acid, or vitamin B12.

Our finding of an inverse association of plasma PLP with the risk of hormone receptor positive breast cancer, but not ER-negative or PR-negative tumors, is novel as no heterogeneity was observed ($P > 0.84$) in the association of circulating PLP with breast cancer risk by hormone receptor status in the Women's Health Study (8). The differential association of PLP with breast cancer risk by hormone receptor status may have biologic relevance as the etiology of these tumors is thought to be distinct (25). Vitamin B6 is a coenzyme in one-carbon metabolism reactions, facilitating the transfer of methyl groups to tetrahydrofolate to yield 5,10-methylenetetrahydrofolate and the downstream generation of thymidylate and purine for DNA synthesis. Disruption of these reactions may create an imbalance in the generation of methyl groups required for DNA methylation and other biochemical processes. Altered DNA methylation has been observed in tumors at several sites (26), and ER and PR expression in breast tumors has found to be associated with methylation of ER and PR gene cytosine-phosphate-guanine (CpG) islands (27, 28).

Experimental studies suggest that supraphysiologic doses of vitamin B6 can reduce tumor cell growth in culture (29–36), including the growth of mammary tumor lines (34–36). The exact mechanism through which vitamin B6 exerts antitumorigenic effects is presently unknown (6). Decreased growth of tumor cells by vitamin B6 treatment has been attributed to modulation of steroid hormone receptor-mediated gene expression (34, 37–39). Because steroid hormones are involved in the regulation of cellular growth, differentiation, and maintenance of physiologic function, the potential for PLP to modulate these hormones could represent a novel therapeutic approach to the inhibition of breast cancer growth. Besides its role in growth regulation, vitamin B6 possesses antiinflammatory properties that might reduce the risk of breast malignancy (40, 41). *In vitro* studies indicate that vitamin B6 may act as an antioxidant (33, 42); thus, the suppressive effects of vitamin B6 on cellular proliferation might be mediated through reduced oxidative stress.

Major strengths of this study include its prospective design and the evaluation of prediagnostic levels of plasma PLP in a large sample of postmenopausal women and controls matched on several factors associated with breast

cancer risk. A wide range of potential confounders of the PLP breast cancer association was available. Furthermore, the measurement of vitamin B6 was conducted by a sensitive tandem mass spectrometry-based method with low interassay variation. Our analysis was limited by a single measurement of PLP, which may not be representative of exposure during periods in a woman's life critical to breast cancer susceptibility and reduces the precision of the measurement. Although, the study sample was relatively large, statistical power to conduct subgroup analyses of hormone-negative tumors was modest.

This nested case-control study provides new evidence that circulating levels of vitamin B6 may be inversely related to the risk of invasive postmenopausal breast cancer. Although, the exact mechanism by which vitamin B6 may reduce the risk of breast cancer is presently unknown, laboratory data are overwhelming that this compound is critical to multiple pathways that might inhibit breast carcinogenesis. In conclusion, these results, in combination with information from 2 other prospective studies, suggest a role for vitamin B6 in the prevention of postmenopausal breast cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: G. Lurie, L.R. Wilkens, B.E. Henderson, L.N. Kolonel, M.T. Goodman

Development of methodology: G. Lurie, L.R. Wilkens, M.T. Goodman
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L.R. Wilkens, L.N. Kolonel

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): G. Lurie, L.R. Wilkens, Y.B. Shvetsov, N.J. Ollberding, A.A. Franke, M.T. Goodman

Writing, review, and/or revision of the manuscript: G. Lurie, L.R. Wilkens, Y.B. Shvetsov, N.J. Ollberding, A.A. Franke, L.N. Kolonel, M.T. Goodman

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.A. Franke, L.N. Kolonel, M.T. Goodman

Study supervision: M.T. Goodman

Acknowledgments

The authors thank Laurie Custer (University of Hawaii Cancer Center) for technical assistance in measuring PLP by LCMS and Stephen Coburn (Purdue University, Fort Wayne, IN) for providing the internal standard for PLP.

Grant Support

The National Cancer Institute and the National Center for Research Resources supported this study by grants P30 CA71789, R37 CA 54281 (L. N. Kolonel) P01 CA 033619 (L.N. Kolonel), and S10 RR020890 (A.A. Franke). The tumor registries in Hawaii and Los Angeles were supported by NCI contracts N01 PC 35137 and N01 PC 35139, respectively.

Received June 13, 2012; revised July 25, 2012; accepted July 30, 2012; published OnlineFirst August 9, 2012.

References

- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011;61:69–90.
- World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition and prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
- Leklem JE. Vitamin B-6: a status report. *J Nutr* 1990;120(Suppl 11):1503–7.
- Bairoch A. The ENZYME database in 2000. *Nucleic Acid Res* 2000;28:304–5.
- Selhub J. Homocysteine metabolism. *Annu Rev Nutr* 1999;19:217–46.

6. Matsubara K, Komatsu S, Oka T, Kato N. Vitamin B6-mediated suppression of colon tumorigenesis, cell proliferation, and angiogenesis (review). *J Nutr Biochem* 2003;14:246–50.
7. Sellers TA, Kushi LH, Cerhan JR, Vierkant RA, Gapstur SM, Vachon CM, et al. Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. *Epidemiology* 2001;12:420–8.
8. Levi F, Pasche C, Lucchini F, La Vecchia C. Dietary intake of selected micronutrients and breast-cancer risk. *Int J Cancer* 2001;91:260–3.
9. Chen J, Gammon MD, Chan W, Palomeque C, Wetmur JG, Kabat GC, et al. One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer. *Cancer Res* 2005;65:1606–14.
10. Lajous M, Lazcano-Ponce E, Hernandez-Avila M, Willett W, Romieu I. Folate, vitamin B(6), and vitamin B(12) intake and the risk of breast cancer among Mexican women. *Cancer Epidemiol Biomarkers Prev* 2006;15:443–8.
11. Chou YC, Lee MS, Wu MH, Shih HL, Yang T, Yu CP, et al. Plasma homocysteine as a metabolic risk factor for breast cancer: findings from a case-control study in Taiwan. *Breast Cancer Res Treat* 2007;101:199–205.
12. Cho E, Holmes M, Hankinson SE, Willett WC. Nutrients involved in one-carbon metabolism and risk of breast cancer among premenopausal women. *Cancer Epidemiol Biomarkers Prev* 2007;16:2787–90.
13. Ma E, Iwasaki M, Junko I, Hamada GS, Nishimoto IN, Carvalho SM, et al. Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Brazilian women. *BMC Cancer* 2009;9:122.
14. Maruti SS, Ulrich CM, White E. Folate and one-carbon metabolism nutrients from supplements and diet in relation to breast cancer risk. *Am J Clin Nutr* 2009;89:624–33.
15. Stevens VL, McCullough ML, Sun J, Gapstur SM. Folate and other one-carbon metabolism-related nutrients and risk of postmenopausal breast cancer in the Cancer Prevention Study II Nutrition Cohort. *Am J Clin Nutr* 2010;91:1708–15.
16. Shrubsole MJ, Shu XO, Li HL, Cai H, Yang G, Gao YT, et al. Dietary B vitamin and methionine intakes and breast cancer risk among Chinese women. *Am J Epidemiol* 2011;173:1171–82.
17. Zhang CX, Ho SC, Chen YM, Lin FY, Fu JH, Cheng SZ. Dietary folate, vitamin B6, vitamin B12 and methionine intake and the risk of breast cancer by oestrogen and progesterone receptor status. *Br J Nutr* 2011;106:936–43.
18. Wu K, Helzlsouer KJ, Comstock GW, Hoffman SC, Nadeau MR, Selhub J. A prospective study on folate, B12, and pyridoxal 5'-phosphate (B6) and breast cancer. *Cancer Epidemiol Biomarkers Prev* 1999;8:209–17.
19. Zhang SM, Willett WC, Selhub J, Hunter DJ, Giovannucci EL, Holmes MD, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. *J Natl Cancer Inst* 2003;95:373–80.
20. Lin J, Lee IM, Cook NR, Selhub J, Manson JE, Buring JE, et al. Plasma folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women. *Am J Clin Nutr* 2008;87:734–43.
21. Zhang SM, Cook NR, Albert CM, Gaziano JM, Buring JE, Manson JE. Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. *JAMA* 2008;300:2012–21.
22. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. *Am J Epidemiol* 2000;151:346–57.
23. Rybak ME, Pfeiffer CM. Clinical analysis of vitamin B(6): determination of pyridoxal 5'-phosphate and 4-pyridoxic acid in human serum by reversed-phase high-performance liquid chromatography with chlorite postcolumn derivatization. *Anal Biochem* 2004;333:336–44.
24. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
25. Zhu K, Davidson NE, Hunter S, Yang X, Payne-Wilks K, Roland CL, et al. Methyl-group dietary intake and risk of breast cancer among African-American women: a case-control study by methylation status of the estrogen receptor alpha genes. *Cancer Causes Control* 2003;14:827–36.
26. Jones PA, Buckley JD. The role of DNA methylation in cancer. *Adv Cancer Res* 1990;54:1–23.
27. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, et al. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. *Clin Cancer Res* 1996;2:805–10.
28. Piva R, Rimondi AP, Hanau S, Maestri I, Alvisi A, Kumar VL, et al. Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor. *Br J Cancer* 1990;61:270–5.
29. DiSorbo DM, Litwack G. Vitamin B6 kills hepatoma cells in culture. *Nutr Cancer* 1982;3:216–22.
30. DiSorbo DM, Wagner R Jr, Nathanson L. *In vivo* and *in vitro* inhibition of B16 melanoma growth by vitamin B6. *Nutr Cancer* 1985;7:43–52.
31. Shultz TD, Santamaria AG, Gridley DS, Stickney DR, Slater JM. Effect of pyridoxine and pyridoxal on the *in vitro* growth of human malignant melanoma. *Anticancer Res* 1988;8:1313–8.
32. Molina A, Oka T, Munoz SM, Chikamori-Aoyama M, Kuwahata M, Natori Y. Vitamin B6 suppresses growth and expression of albumin gene in a human hepatoma cell line HepG2. *Nutr Cancer* 1997;28:206–11.
33. Komatsu SI, Watanabe H, Oka T, Tsuge H, Nii H, Kato N. Vitamin B-6-supplemented diets compared with a low vitamin B-6 diet suppress azoxymethane-induced colon tumorigenesis in mice by reducing cell proliferation. *J Nutr* 2001;131:2204–7.
34. Davis BA, Cowing BE. Pyridoxal supplementation reduces cell proliferation and DNA synthesis in estrogen-dependent and -independent mammary carcinoma cell lines. *Nutr Cancer* 2000;38:281–6.
35. Shimada D, Fukuda A, Kanouchi H, Matsumoto M, Oka T. Vitamin B6 suppresses growth of the feline mammary tumor cell line FRM. *Biosci Biotechnol Biochem* 2006;70:1038–40.
36. Shimada D, Fukuda A, Kawaguchi H, Kato N, Yoshida H, Kanouchi H, et al. Effect of high dose of pyridoxine on mammary tumorigenesis. *Nutr Cancer* 2005;53:202–7.
37. Cidlowski JA, Thanassi JW. Pyridoxal phosphate: a possible cofactor in steroid hormone action. *J Steroid Biochem* 1981;15:11–6.
38. Allgood VE, Cidlowski JA. Vitamin B6 modulates transcriptional activation by multiple members of the steroid hormone receptor superfamily. *J Biol Chem* 1992;267:3819–24.
39. Oka T. Modulation of gene expression by vitamin B6. *Nutr Res Rev* 2001;14:257–66.
40. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. *Circulation* 2001;103:2788–91.
41. Morris MS, Sakakeeny L, Jacques PF, Picciano MF, Selhub J. Vitamin B-6 intake is inversely related to, and the requirement is affected by, inflammation status. *J Nutr* 2010;140:103–10.
42. Jain SK, Lim G. Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na⁺ + K⁺)-ATPase activity reduction in high glucose-treated human erythrocytes. *Free Radic Biol Med* 2001;30:232–7.